论文部分内容阅读
Objective Tumors often contain hypoxic regions resistant to chemo-and radiotherapy.TH-302 is an investigational hypoxia-activated prodrug that selectively releases the DNA cross-linker bromo-isophosphoramide mustard under hypoxic conditions.